$MRLN Part 2: Stress-Tested and Standing
Crossroads-calibrated valuation with preferred shares, full ratchet anti-dilution, and worst-case dilution. A follow-up to 54x Upside Hiding in a De-SPAC
Shawarma Capital · April 2026
In our first post, we laid out the full Merlin Labs ($MRLN) thesis: the Brainstem, the A-GRA architecture, the $105M USSOCOM IDIQ, and why this might be the most asymmetric name in defense tech.
But one thing we didn't do is stress-test the valuation against the ugly stuff.
The PIPE terms. The Series A Preferred shares carrying a 12% cumulative dividend ($31.3M/year accruing whether they pay it or not). The full ratchet anti-dilution. The 129.4M actual shares outstanding vs. the 101.06M pro forma count Crossroads used.
Where this builds on Crossroads Capital:
Crossroads published a strong foundational case for MRLN in March 2026. Their analysis was the first serious attempt to quantify Merlin's long-duration value, and it established the defense AI multiple framework that this report builds on. But it had gaps: the share count was understated (101.06M vs. 129.4M actual), the dilution analysis was incomplete, and the preferred stock terms were not modeled. This V2 report takes the Crossroads framework and makes it airtight by fixing the share count, separating dilution from multiple methodology, modeling the preferred structure, and adding year-by-year peer-calibrated multiples instead of single-point maturity estimates.
The bottom line: even after accounting for worst-case dilution, the expected value math still works. The probability-weighted expected value across all scenarios is ~$102/share from a $7 entry, implying 15x expected return over 6 years.
Every table, every chart, every assumption laid bare.
Executive Summary
Merlin Labs (NASDAQ: MRLN) develops aircraft-agnostic AI autonomous flight software for military and commercial aircraft. The company listed via SPAC on March 17, 2026 with FY2025 revenue of $7.55M and 2026 guidance of ~$32M (+324% YoY). This V2 report rebuilds the valuation using Crossroads Capital's defense AI multiples (7.5x to 20x on maturity ARR), peer-validated assumptions from Palantir, Anduril, and Shield AI, and the corrected 129.4M share count.
The table below summarizes the scenario outputs across key years:
All price targets on 129.4M current shares outstanding. See dilution section for fully diluted adjustments. Current price ~$6-8 (April 2026).
Capital Structure & Dilution Analysis
This section isolates the capital structure and quantifies dilution impact on Crossroads' targets independently of EV/Revenue methodology.
Share Count Breakdown
Impact on Crossroads Price Targets
Crossroads used 101.06M pro forma shares. Actual outstanding is 129.4M, a 28% increase that mechanically reduces all per-share targets. At maturity, if all convertible instruments exercise, shares reach ~162.2M, a 60.5% increase over Crossroads' count.
Key finding: Dilution alone accounts for a ~38% reduction from Crossroads' published targets to fully diluted values. This is a purely mechanical share-count adjustment that does NOT change the enterprise value assessment.
Series A Preferred Stock Detail
If stock exceeds $12 at maturity (true in all scenarios), preferred converts to common, adding ~21.7M shares but eliminating the $260.6M liquidation preference and $187.8M accrued dividends. Conversion is shareholder-friendly at high prices; punitive in distressed scenarios where liquidation preference takes priority.
Revenue Projections 2025 to 2032
Revenue is modeled from Merlin's per-aircraft unit economics ($3M integration + $2M/year recurring license) applied to fleet penetration scenarios. FY2025 actual ($7.55M) and 2026 management guidance ($32M) anchor all scenarios. Divergence begins in 2027 based on program expansion and new contract wins.
EV/Revenue Multiple Methodology
V2 uses defense AI software multiples calibrated to actual peer transactions at equivalent revenue stages. Each year's applied multiple reflects where MRLN sits on the defense AI maturity curve, grounded in real-world comparable deal data.
Peer-Calibrated Multiple Justification
Crossroads Maturity Multiple Rationale
Defense Software vs. Hardware Multiples
Year-by-Year Implied Valuation
Revenue projections combined with stage-appropriate multiples produce implied stock prices for each year. Prices shown on both current (129.4M) and fully diluted (162.2M) share counts.
Bear Case: C-130J Only, Delayed Execution
Base Case: C-130J + KC-135, On-Schedule
Bull Case: Multi-Platform + CCA Expansion
Peer Comparable Deep Dives
Palantir: The Defense AI Blueprint
Palantir is the most direct long-duration comparable. Both are government-first AI software companies that spent years pre-profit before explosive growth. Palantir's multiple ranged from 6x (2022 trough) to 96x (2025 peak), re-rated by five specific catalysts.
Anduril: Revenue Scaling Benchmark
Shield AI: Defense Autonomy Premium
42x on $300M revenue, justified by CCA contract (largest drone program in history), 130+ Ukraine combat sorties proving GPS-denied autonomy, and Hivemind software at ~30% of revenue targeting 50% by 2028. Most direct structural comp to MRLN's military aviation AI thesis.
Success & Failure Case Studies
Revenue Scaling: Successes
Failed Defense SPACs
MRLN vs. Failed SPACs
Re-Rating Catalysts & Timeline
Multiple expansion in defense AI is catalyst-driven, not gradual. Palantir re-rated 16x (from 6x to 96x) through five discrete events. MRLN's trajectory depends on similar milestones.
Precedent: Palantir tripled in 2023 on two catalysts (GAAP profit + AIP launch). Shield AI doubled its valuation in one quarter after winning CCA. Defense AI re-ratings are abrupt and large.
Additive Thesis: CCA / A-GRA Layer 3 (Shawarma Capital)
Shawarma Capital identifies an additive revenue stream not in the Crossroads model: the USAF's A-GRA architecture requires a DO-178C Level A certified "brainstem" (Layer 3) for flight control on Collaborative Combat Aircraft. Merlin is one of only two companies (with Reliable Robotics) with the certification pedigree and a signed CRADA for this role.
Sensitivity Analysis & Expected Value
Maturity Sensitivity: Aircraft x Multiple (129.4M shares)
Base Rate Analysis
Probability-Weighted Expected Value (2032)
Expected value: $102/share on a $7 entry, implying 15x expected return over 6 years. Asymmetry driven by base case ($213) and bull case ($294) contributing disproportionately to EV.
Sensitivity to Probability Assumptions
Cash Runway & Risk Assessment
Cash Flow Model
Runway: ~$146M starting cash at ~$50-60M/year net burn provides 2.5-3 years of runway (through mid-2028). Revenue growth to $86M+ in 2027 should reduce net burn materially, potentially extending runway to 2029+ without additional capital. If growth disappoints, a dilutive raise in 2027-2028 becomes necessary, and full ratchet anti-dilution on the preferred amplifies the impact of any below-$10 raise.
Risk Matrix
Investment Conclusion
MRLN presents a high-conviction, high-risk, asymmetric return profile. The V2 model using Crossroads-calibrated defense AI multiples produces:
• The asymmetry is real. Even the bear case ($41 on 129.4M shares) implies ~5.9x upside from $7, requiring only that Merlin execute on its existing C-130J contract at compressed 7.5x multiples. Total loss requires burning through $146M without delivering meaningful product.
• Near-term is catalyst-driven. MRLN will likely trade $5-12 until CDR passage, analyst initiation, or contract expansion materialize. The market cannot price a $37B maturity EV today. It prices the probability and timing of those catalysts.
• Preferred structure is a burden, not a killer. The $31.3M/year accrual is meaningful but at 20x on $1.6B ARR, the accumulated $448M preferred claim is 1.2% of enterprise value.
• Expected value: ~$102/share under moderate assumptions (25% loss / 35% bear / 30% base / 10% bull), implying ~15x expected return from $7 over 6 years.
Sources
1. Crossroads Capital: "The Long Duration Case for Merlin Labs," March 23, 2026
2. Shawarma Capital: "$MRLN: 54x Upside Hiding in a De-SPAC," April 8, 2026
3. SEC: MRLN FY2025 Results (Exhibit 99-2)
4. StockAnalysis: MRLN Statistics & Financials, April 2026
5. Contrary Research: Anduril Industries Full Profile
6. Sacra: Shield AI Revenue & Valuation
7. Fortune: Shield AI $12.7B Series G, March 2026
8. Finbox: Palantir EV/Revenue History
9. GuruFocus: Palantir EV/Revenue Historical Range
10. DOL/Signac LLC: Palantir IPO Valuation Expert Analysis
11. Washington Technology: Merlin Labs IPO Coverage, March 2026
12. MarketScreener: Rocket Lab Valuation History
13. TSG Invest: Anduril Valuation History
14. Fast Company: IronNet Cybersecurity, Rise and Fall
15. J.P. Morgan: Defense Tech Innovation & Startup Base Rates
16. Aventis Advisors: AI Startup Valuation Multiples 2025
17. HBS (Shikhar Ghosh): VC-Backed Company Failure Rates
18. CNBC: Palantir S&P 500 Inclusion, September 2024
I am long $MRLN equity. This is research synthesis, not investment advice. You should not buy or sell securities based on anything I write. I am not a registered investment advisor; I do not owe you a fiduciary duty; my conclusions could be wrong in ways I have not anticipated. Do your own due diligence.
I think you uploaded the wrong article 🙂. This is the same as the 3rd part?